Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

Journal of Drug Targeting

Volumn 16, Issue 7-8, 2008, Pages 626-637

  Zavaleta, Cristina ^a   Goins, Beth ^a   Bao, Ande ^a   Mcmanus, Linda ^b   Mcmahan, C Alex ^b   Phillips, William ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Avidin; Biotin liposomes; Intraperitoneal delivery; Positron emission tomography; Radionuclide therapy; Single photon emission computed tomography

Indexed keywords

AVIDIN; BIOTIN; FLUORODEOXYGLUCOSE F 18; LIPOSOME; RHENIUM 186; DIAGNOSTIC AGENT; RHENIUM;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES CELL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG RESPONSE; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; LIPOSOMAL DELIVERY; MAXIMUM TOLERATED DOSE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SCINTIGRAPHY; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; DOMESTIC ANIMAL; DRUG DELIVERY SYSTEM; NUDE RAT; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANIMALS, DOMESTIC; DRUG DELIVERY SYSTEMS; FEMALE; FLUORODEOXYGLUCOSE F18; LIPOSOMES; MAXIMUM TOLERATED DOSE; RATS; RATS, NUDE; RHENIUM; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 49149122091     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802230372     Document Type: Article

References (42)

1. Agarwal, R., Linch, M. and Kaye, SB (2006) Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol, 32, pp. 875-886.
2. Bao, A., Goins, B., Klipper, R., Negrete, G. and Phillips, WT (2003) 186Re-liposome labeling using 186Re-SNS/S complexes: In vitro stability, imaging, and biodistribution in rats. J Nucl Med, 44, pp. 1992-1999.
3. Bao, A., Goins, B., Klipper, R., Negrete, G. and Phillips, WT (2004) Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther, 308, pp. 419-425.
4. Buchsbaum, DJ, Khazaeli, MB, Axworthy, DB, Schultz, J., Chaudhuri, TR, Zinn, KR, Carpenter, M. and LoBuglio, AF (2005) Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res, 11, pp. 8180-8185.
5. Caliceti, P., Chinol, M., Roldo, M., Veronese, FM, Semenzato, A., Salmaso, S. and Paganelli, G. (2002) Poly(ethylene glycol)-avidin bioconjugates: Suitable candidates for tumor pretargeting. J Control Release, 83, pp. 97-108.
6. Cannistra, SA (2006) Intraperitoneal chemotherapy comes of age. N Engl J Med, 354, pp. 77-79.
7. Chan, JK, Cheung, MK, Husain, A., Teng, NN, West, D., Whittemore, AS, Berek, JS and Osann, K. (2006) Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol, 108, pp. 521-528.
8. Chen, LC, Chang, CH, Yu, CY, Chang, YJ, Hsu, WC, Ho, CL, Yeh, CH, Luo, TY, Lee, TW and Ting, G. (2007) Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol, 34, pp. 415-423.
9. Chinol, M., Casalini, P., Maggiolo, M., Canevari, S., Omodeo, ES, Caliceti, P., Veronese, FM, Cremonesi, M., Chiolerio, F. Nardone, E. et al. (1998) Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer, 78, pp. 189-197.
10. Coliva, A., Zacchetti, A., Luison, E., Tomassetti, A., Bongarzone, I., Seregni, E., Bombardieri, E., Martin, F., Giussani, A. Figini, M. et al. (2005) 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother, 54, pp. 1200-1213.
11. de Bree, E., Witkamp, AJ and Zoetmulder, FA (2002) Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol, 79, pp. 46-61.
12. Deutsch, E., Libson, K., Vanderheyden, JL, Ketring, AR and Maxon, HR (1986) The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B, 13, pp. 465-477.
13. Elgqvist, J., Andersson, H., Back, T., Hultborn, R., Jensen, H., Karlsson, B., Lindegren, S., Palm, S., Warnhammar, E. and Jacobsson, L. (2005) Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med, 46, pp. 1907-1915.
14. Gadducci, A., Cosio, S., Conte, PF and Genazzani, AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol, 55, pp. 153-166.
15. Grana, C., Bartolomei, M., Handkiewicz, D., Rocca, P., Bodei, L., Colombo, N., Chinol, M., Mangioni, C., Malavasi, F. and Paganelli, G. (2004) Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with (90)Y-biotin?. Gynecol Oncol, 93, pp. 691-698.
16. Gunn, AJ, Brechbiel, MW and Choyke, PL (2007) The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. Expert Opin Drug Deliv, 4, pp. 389-402.
17. Hagenbeek, A. (2005) Future trends in radioimmunotherapy. Semin Oncol, 32, pp. S57-S62.
18. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, MJ (2007) Cancer statistics, 2007, CA. Cancer J Clin, 57, pp. 43-66.
19. Koppe, MJ, Postema, EJ, Aarts, F., Oyen, WJ, Bleichrodt, RP and Boerman, OC (2005) Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev, 24, pp. 539-567.
20. Markman, M. (2001) Intraperitoneal drug delivery of antineoplastics. Drugs, 61, pp. 1057-1065.
21. Markman, M. (2003) Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol, 4, pp. 277-283.
22. McQuarrie, S., Mercer, J., Syme, A., Suresh, M. and Miller, G. (2005) Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci, 7, pp. 29-34.
23. Medina, LA, Calixto, SM, Klipper, R., Li, Y., Phillips, WT and Goins, B. (2006) Mediastinal node and diaphragmatic targeting after intracavitary injection of avidin/99mTc-blue-biotin-liposome system. J Pharm Sci, 95, pp. 207-224.
24. Meredith, RF, Buchsbaum, DJ, Alvarez, RD and LoBuglio, AF (2007) Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res, 13, pp. 5643s-5645s.
25. Munoz-Casares, FC, Rufian, S., Rubio, MJ, Lizarraga, E., Diaz-Iglesias, C., Aranda, E., Ciria, R., Muntane, J., Barrios, P. Torres-Melero, J. et al. (2007) Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals. Clin Transl Oncol, 9, pp. 652-662.
26. Oriuchi, N., Higuchi, T., Hanaoka, H., Iida, Y. and Endo, K. (2005) Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med, 19, pp. 355-365.
27. Parker, RJ, Hartman, KD and Sieber, SM (1981) Lymphatic absorption and tissue disposition of liposome-entrapped [14C]adriamycin following intraperitoneal administration to rats. Cancer Res, 41, pp. 1311-1317.
28. Parker, RJ, Sieber, SM and Weinstein, JN (1981) Effect of liposome encapsulation of a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology, 23, pp. 128-136.
29. Phillips, WT, Klipper, R. and Goins, B. (2001) Use of (99m)Tc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med, 42, pp. 446-451.
30. Phillips, WT, Medina, LA, Klipper, R. and Goins, B. (2002) A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J Pharmacol Exp Ther, 303, pp. 11-16.
31. Reddy, LH and Murthy, RS (2004) Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 148, pp. 161-166.
32. Sadzuka, Y., Hirama, R. and Sonobe, T. (2002) Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicol Lett, 126, pp. 83-90.
33. Schneider, JG (1994) Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am, 21, pp. 195-212.
34. Stewart, JC (1980) Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem, 104, pp. 10-14.
35. Twardowski, ZJ (2006) History of peritoneal access development. Int J Artif Organs, 29, pp. 2-40.
36. Varia, MA, Stehman, FB, Bundy, BN, Benda, JA, Clarke-Pearson, DL, Alvarez, RD and Long, HJ (2003) Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: A randomized trial of the Gynecologic Oncology Group. J Clin Oncol, 21, pp. 2849-2855.
37. Woodward, PJ, Hosseinzadeh, K. and Saenger, JS (2004) From the archives of the AFIP: Radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics, 24, pp. 225-246.
38. Xiao, Z., McQuarrie, SA, Suresh, MR, Mercer, JR, Gupta, S. and Miller, GG (2002) A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol, 94, pp. 171-184.
39. Young, RC, Brady, MF, Nieberg, RK, Long, HJ, Mayer, AR, Lentz, SS, Hurteau, J. and Alberts, DS (2003) Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J Clin Oncol, 21, pp. 4350-4355.
40. Zavaleta, CL, Phillips, WT, Bradley, YC, McManus, LM, Jerabek, PA and Goins, BA (2007) Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging. Int J Gynecol Cancer, 17, pp. 407-417.
41. Zavaleta, CL, Phillips, WT, Soundararajan, A. and Goins, BA (2007) Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model. Int J Pharm, 337, pp. 316-328.
42. Zweit, J. (1996) Radionuclides and carrier molecules for therapy. Phys Med Biol, 41, pp. 1905-1914.